Morgan Stanley upgrades Gilead on HIV treatment growth
Morgan Stanley upgraded Gilead Sciences Inc (NASDAQ:GILD) to "overweight" from "equal weight," raising its price target to $113 from $87 on HIV prevention drug Lenacapavir (PrEP) and next-gen HIV treatments.
Gilead upgraded by Morgan Stanley on lenacapavir potential
Morgan Stanley has upgraded Gilead Sciences (NASDAQ:GILD) to overweight from equal weight, citing the company's HIV drug lenacapavir. The investment bank said it was "leaning into the bull case," seeing "the potential for upward estimate revisions on lenacapavir for PrEP and further multiple expansion as the company makes progress with its
Morgan Stanley Upgrades Vir Biotechnology (VIR)
Fintel reports that on January 9, 2025, Morgan Stanley upgraded their outlook for Vir Biotechnology (NasdaqGS:VIR) from Equal-Weight to Overweight. Analyst Price Forecast Suggests 141.11% Upside As of December 23,
Morgan Stanley (MS) Earnings Expected to Grow: Should You Buy?
Morgan Stanley (MS) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture,
Vir Biotech upgraded at Morgan Stanley on cancer drug data
Morgan Stanley upgraded Vir Biotechnology (NASDAQ:VIR) to Overweight from Equal Weight on Thursday after the cancer drug developer shared initial mid-stage trial data for two antitumor agents developed using Sanofi’s (SNY) PRO-XTEN masking platform.
Morgan Stanley upgrades Vir Biotechnology to 'overweight,' raises PT to $20
Morgan Stanley (NYSE:MS) analysts have upgraded Vir Biotechnology (NASDAQ:VIR) to an "overweight" rating, shifting from "equal-weight," and have also increased their price target to $20 from $10. The analysts flagged
This HIV drug is hailed as 2024's Discovery of the Year
A milestone was reached in the fight against HIV/AIDS with the development of Lenacapavir, a new injectable drug that ...
‘Pivotal step’: University of Utah biochemist’s HIV research contributes to Science’s ‘Breakthrough of the Year’
Wesley Sundquist’s lab laid foundation for development of a highly effective, long-lasting preventive measure against HIV.
Armed robbery in Revesby7d
WHO Unveils New Lenacapavir, HIV Testing Guidelines
WHO is convening a Guideline Development Group (GDG) for the development of new guidelines on the use of injectable ...
MIT Technology Review9d
Long-acting HIV prevention meds: 10 Breakthrough Technologies 2025
A new drug is hugely effective at protecting people from HIV infection and needs to be injected only twice a year.
Glassman: How Trump can meet his goal of ending AIDS
In Donald Trump’s 2019 State of the Union Address, he made “a commitment to eliminate the HIV epidemic in the United States ...
HIV drug lenacapavir is a breakthrough in treating AIDS
The US drug administration has approved the use of the medication as an injection for use against the multidrug resistant ...
Managed Healthcare Executive5d
WHO to Develop Lenacapavir and HIV Testing Guidelines
A Guideline Development Group (GDG) meeting at the end of the month aims to establish new guidelines for lenacapavir, a twice ...
Newsweek9d
HIV in 2025: 'There Is Hope for the Future,' Say Disease Experts
The 2024 breakthrough of the year, according to the journal Science, was with the drug lenacapavir, an antiretroviral medicine that performed very well in scientific trials. Dr. Robert Hopkins Jr ...
Opinion
2024 was a good year for medical progress. But that alone won’t save us.
This year we saw more examples of the destructive effort to undermine abortion as a health service. But overreach into health practices was not limited to abortion care.
Mena FN6d
WHO Announces The Development Of New Guidelines For Lenacapavir And Updated HIV Testing Guidelines
(MENAFN- Caribbean News Global) GENEVA, Switzerland – WHO is convening a Guideline Development Group (GDG) for the development of new guidelines on the use of injectable lenacapavir as pre ...
Investing3d
Morgan Stanley lifts Gilead stock to Overweight on Lenacapavir potential
The firm highlighted that Gilead's shares have seen a rise due to positive developments in its pipeline, particularly for Lenacapavir in HIV prevention and anito-cel in multiple myeloma. Gilead's ...